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Clinical Research Article
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Abstract
Context: Glycogen storage diseases are rare. Increased glycogen in the liver results in
increased attenuation.
Objective: Investigate the association and function of a noncoding region associated
with liver attenuation but not histologic nonalcoholic fatty liver disease.
Design: Genetics of Obesity-associated Liver Disease Consortium.
Setting: Population-based.
Main Outcome: Computed tomography measured liver attenuation.
Results: Carriers of rs4841132-A (frequency 2%-19%) do not show increased hepatic
steatosis; they have increased liver attenuation indicative of increased glycogen
deposition. rs4841132 falls in a noncoding RNA LOC157273 ~190 kb upstream of
PPP1R3B. We demonstrate that rs4841132-A increases PPP1R3B through a cis genetic
effect. Using CRISPR/Cas9 we engineered a 105-bp deletion including rs4841132-A in
human hepatocarcinoma cells that increases PPP1R3B, decreases LOC157273, and
increases glycogen perfectly mirroring the human disease. Overexpression of PPP1R3B
or knockdown of LOC157273 increased glycogen but did not result in decreased
LOC157273 or increased PPP1R3B, respectively, suggesting that the effects may
not all occur via affecting RNA levels. Based on electronic health record (EHR) data,
rs4841132-A associates with all components of the metabolic syndrome (MetS). However,
rs4841132-A associated with decreased low-density lipoprotein (LDL) cholesterol and risk
for myocardial infarction (MI). A metabolic signature for rs4841132-A includes increased
glycine, lactate, triglycerides, and decreased acetoacetate and beta-hydroxybutyrate.
Conclusions: These results show that rs4841132-A promotes a hepatic glycogen storage
disease by increasing PPP1R3B and decreasing LOC157273. rs4841132-A promotes
glycogen accumulation and development of MetS but lowers LDL cholesterol and risk
for MI. These results suggest that elevated hepatic glycogen is one cause of MetS that
does not invariably promote MI.
Key Words: genetics, NALFD, glycogen, GWAS, triglyceride, metabolic syndrome
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Methods
Genetics of Obesity-associated Liver Disease
Consortium
Eight cohorts (n = 16 234) with Illumina Exome array data
were included (Supplementary Tables 1-5 (4)): AGES (5),
FamHS (6), FHS (7), GENOA (8), IRASFS (9), JHS (10),
MESA (11), and OOA (12, 13). All work was approved by
local institutional review boards or equivalent committees
and participants provided written informed consent.
Studies calculated a ratio of liver attenuation to external
phantom (or spleen) for each individual to control for scan
penetrance. Values were inverse normalized and regressed
against variants for association using linear regression
modeling (linear mixed modeling for related individuals)
controlling for age, age2, sex, principal components, and
study site (where appropriate). Variants with a minor allele
count > 6, Hardy-Weinberg Equilibrium P > 1 × 10–6 and
call rate > 98% from each study that did not have significant
P values for heterogeneity were included. Variants in/near
PPP1R3B were analyzed for association and results combined using a fixed effects meta-analysis in METAL (14).

UK Biobank Liver Fat Analyses
UK Biobank (UKBB) liver fat analyses were performed
under Resource Project #18120. Briefly, UKBB is a prospective epidemiological study of phenotyped individuals
aged 40 to 69 at the time of recruitment from the United
Kingdom who have been genotyped (15). Genotypes of
the UKBB participants were assayed using either of two
genotyping arrays, the Affymetrix UK BiLEVE Axiom
array or Affymetrix UKBiobank Axiom array. These arrays were augmented by imputation of ~96 million genetic variants from the Haplotype Reference Consortium
(http://www.haplotype-reference-consortium.org/), 1000
Genomes (https://www.internationalgenome.org/), and the
UK 10K (https://www.uk10k.org/) projects. Individuals
were excluded if they were designated by the UKBB as outliers based on either genotyping missingness rate or heterogeneity, whose sex inferred from the genotypes did not
match their self-reported sex and who were not of white
British ancestry. Finally, individuals were removed if they
had missingness > 5% across variants which passed quality
control procedures. Characteristics of the participants
(N = 408 961) are shown in Supplementary Table 6 (4).
Association analyses were carried out for inverse normally
transformed liver magnetic resonance imaging proton
density fat fraction in UKBB using linear mixed modeling
controlling for sex, array batch, UKBB Assessment Center,
age, age2, and the first 10 genomic principal components
using SAIGE (16). Imputation quality scores (IQS) for
rs4841132 (IQS = 1), rs738409 (IQS = 1), rs58542926
(IQS = 1), rs378140 (IQS = 0.99), and rs61756425
(IQS = 1) were excellent.

Michigan Genomics Initiative Cohort
University of Michigan Health System patients were recruited on the day of their elective procedure using an
opt-in written informed consent for broad long-term use of
their electronic health information and genetic data (17).
Laboratory values, diagnoses, demographics, and vital
signs were extracted for patients seen between January
2012 and December 31, 2015. All available laboratory
values were extracted and the mean ± SD for each trait
and each individual calculated with exclusion of measures that were > 1 SD to decrease entry errors. Continuous
traits were inverse normally transformed. NAFLD was
identified by International Classification of Diseases, 9th
edition (ICD-9; before 2015) or ICD-10 (after 2015) diagnoses: 571.8 and K76.0. Cirrhosis was identified using
ICD-10 diagnosis: K70.2, K70.3, K70.4, K71.7, and
K.74*. Characteristics of the participants are shown in
Supplementary Table 7 (4). Genotyping was performed on
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Glycogen storage diseases are caused by excess glycogen
storage in tissues. Previously characterized glycogen
storage diseases are rare, most being less than 1 in 20 000
live births (1). Increased glycogen accumulation in the liver
results in increased liver attenuation. Genetic variants that
increase liver attenuation in the population have not been
fully explored.
We previously carried out a genome-wide association
study (GWAS) of liver attenuation measured by computed
tomography (CT) in individuals of European ancestry (2).
The minor allele (A) of rs4240624 associated with increased
liver attenuation, suggestive of increased liver glycogen.
Importantly, rs4240624 did not significantly associate
with histologic measures of nonalcoholic fatty liver disease
(NAFLD), including steatosis, nonalcoholic steatohepatitis,
and fibrosis in multiple studies (2, 3). We have since noted
that the liver attenuation altering variants map to a long
noncoding RNA LOC157273 ~190 kb upstream of a putative glycogen metabolism regulating gene, PPP1R3B. To
investigate how these variants contribute to human disease,
we carried out association analyses of the most significantly
associated liver attenuation variant, rs4841132 (r2 = 0.99
with rs4240624) across multiple diseases and traits. We
also examined how this variant affected gene expression
in multiple tissues and datasets. We deleted the region
containing this variant in a human liver hepatocarcinoma
cell line and we examined how it affected PPP1R3B and
LOC157273 RNA levels as well as glycogen.
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Massachusetts General Hospital Biopsies
Liver (n = 566), subcutaneous (N = 608), and omental
fat (n = 741) were obtained from patients undergoing
bariatric surgery. RNA expression was assessed using a
custom Agilent microarray targeting 34 694 known/predicted genes. Genotyping was performed on the Illumina
650Y array (18). eQTLs were called using Matrix EQTL
(https://cran.r-project.org/web/packages/MatrixEQTL/),
running a linear model with a window of ±1 Mb for cis
eQTLs. Conditional analysis was run using stepwise linear
regression.

STARNET Liver Biopsies
Liver tissue from 600 coronary artery disease patients in the Stockholm-Tartu Atherosclerosis Reverse
Networks Engineering Task (STARNET) study were
used (19). Samples were genotyped using the Illumina
OmniExpressExome-8v1 array. RNA sequencing was carried out using the Illumina TruSeq stranded mRNA kit followed by mapping reads with STAR v.2.3.0e (20) (Genome
Reference Consortium GRCh37). Gene expression was determined using DESeq2 v.1.8.1 (21) adjusted for age, sex,
protocol, and laboratory covariates. Conditional analyses
were carried out as in the Massachusetts General Hospital
(MGH) sample.
Allelic expression imbalance was fit to 1 of 2 models
in R. For rs4841132, a binomial model was used to test
for imbalance between expression of the A/G alleles in heterozygotes (confirmed by genotyping) only. For PPP1R3B,
rs330915 in the 3′ UTR was used to identify allele-specific
expression and the rank of the absolute level of imbalance
was regressed in a generalized linear model against whether
the sample was heterozygous at rs4841132 (22-24). Causal
inference analysis (25) was used with rs4841132 designated
as the locus and PPP1R3B expression as the outcome/trait.

Functional Analysis in HuH-7 Cell Lines
The HuH-7 human hepatocarcinoma cell line (26) was
used for functional analyses. The Alt-R CRISPR-Cas9
System (Integrated DNA Technologies) was used to produce a 105-bp deletion of exon 2 in LOC157273 including
the variant rs4841132. In a separate set of experiments, the
same system was used to produce a homozygous frameshift by the insertion of a T in the codon for amino acid

10 in the PPP1R3B gene. Guide RNA oligonucleotide
sequences are shown in Supplementary Table 8 (4). Briefly,
cells were seeded into 6-well plates with complete DMEM
medium with 10% fetal bovine serum (FBS) plus 100 IU/
mL penicillin and 100 µg/mL streptomycin at a density
of 3 × 105 cells per well. After 24 hours, cells were transfected with either PPP1R3B or rs4841132 complexes (ie,
gRNA+tracrRNA and Cas9 nuclease) using Lipofectamine
RNAi Max transfection reagent (Thermo Fisher Scientific).
DMEM medium was replaced 48 hours posttransfection
and cells cultured for 2 days. Cells were single-cell cloned
by limiting dilution. After 10 days, 50 µL 1× TrypLE enzyme solution was added to each well, transferred into 6
wells each, and cultured for 3 days in DMEM. DNA was
isolated, PCR was performed around the putative insertion/
deletion, and editing confirmed with Sanger sequencing.
For overexpression experiments, an overexpression
plasmid for LOC157273 was made by transferring the
LOC157273 cDNA into the pCMV6-Entry vector using the
Gibson cloning kit with Q5 High-Fidelity DNA Polymerase
(New England Biolabs). The cDNA insert was verified by
EcoRI digest and bidirectionally sequenced using tiled primers with > 2× coverage. An overexpression plasmid for
PPP1R3B was made by transferring the PPP1R3B cDNA
cloned from MGH clone plasmid 50661 into the HinDIII
site of pCMV6-Entry vector using the Gibson cloning kit
with Q5 High-Fidelity DNA Polymerase (New England
Biolabs). The cDNA insert was verified by EcoRI digest
and bidirectionally sequenced using tiled primers with > 2×
coverage.
For knockdown experiments, HuH-7 cells were seeded
at a density of 2 × 105 cells per well in 6-well plates in
C-DMEM medium. After 24 hours’ culture, 10 nM (final
concentration) of LOC157273 antisense oligonucleotide
(ASO) scramble 2 and 3 or a mixture of LOC157273 ASO1,
ASO2, ASO3, ASO4, and ASO5 was transfected into cells
using FUGENE-HD transfection reagent (Promega, WI).
Cells were cultured for an additional 24 hours and then
assayed. Antisense oligonucleotide sequences are shown in
Supplementary Table 8 (4).

RT-quantitative PCR and Glycogen Assays for
30 nM Insulin and 200 µM BSA-bound Oleic
Acid-treated LOC157273 105-bp Deletion in
HuH-7 Cells
For LOC157273 105-bp deletion cell line studies, cells
including mock, LOC157273 105-bp homozygous deletion, and LOC157273 105-bp heterozygous deletion cell
lines were seeded in 12-well plates (5 × 105 cells/well).
Cells were maintained at 37°C in 5% CO2 in low glucose
(5.5 mM) DMEM medium with 10% FBS and 100 U/
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the Illumina HumanCoreExome array. IQS for rs4841132
(IQS = 1), rs738409 (IQS = 1), rs58542926 (IQS = 1),
rs378140 (IQS = 0.88), and rs61756425 (IQS = 0.99) were
excellent.
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RT-qPCR and Glycogen Assays for 30 nM Insulin
and 200 µM BSA-bound Oleic Acid-treated
LOC157273 Overexpression in HuH-7 Cells
For LOC157273 overexpression studies, cells were
transfected with the pCMV6-Entry vector expressing
LOC157273 cDNA or a control empty pCMV6-Entry
vector using FuGENE transfection reagent (Thermo
Scientific). Posttransfection (48 hours), cells stably expressing these genes were selected with G-418 for 72
hours. Medium was changed and fresh G-418 was added
every 2 days. After 3 days, cells stably overexpressing the
LOC157273 were collected and the total cellular RNA extracted using TRIzol reagent. Overexpression was measured and confirmed by RT-qPCR assay. Stable LOC157273
overexpressing sublines were cultured in high glucose
(25 mM) DMEM with 10% FBS and G-418 (10 µg/mL).
After 24 hours, the medium was replaced with DMEM
with 10% delipidated FBS and G-418 for another 24 hours.
Then 30 nM insulin or 200 µM of BSA-bound oleic acid
was added to culture medium. For the control group, the
same volume of treatment DMEM medium was added into
each well. After an additional 24 hours of incubation with

insulin or oleic acid, cells were collected and cell lysis with
RIPA buffer (200 µL/well) for protein sample and RNA
samples were isolated from these cells by using TRIzol reagent. Cellular glycogen was extracted and quantified using
the Glycogen Assay and Serum Triglyceride Determination
kits (Sigma-Aldrich). Values were normalized by total cellular protein amount. LOC157273 and PPP1R3B expression levels were measured using RT-qPCR assay (Thermo
Scientific, HS01934960). Experiments were done in 6 replicates and differences were evaluated using a paired t test.
Difference between experimental group and control group
was considered significant at P < 0.05.

RT-qPCR and Glycogen Assays for 30 nM Insulin
and 200 µM BSA-bound Oleic Acid-treated
LOC157273-ASO Knock Down in HuH-7 Cells
For knockdown experiments, HuH-7 cells were seeded at
a density of 1.5 × 105 cells/well in 12-well plates in high
glucose C-DMEM medium. After 24 hours, 20 nM (final
concentration) of scrambled DNA 2 and 3 or a mixture
of LOC157273 ASOs were transfected into cells using
FUGENE-HD transfection reagent (Promega, WI). Cells
were transfected for 24 hours and then C-DMEM medium
was replaced with high glucose (25 mM) DMEM medium
with 10% delipidated FBS for 24 hours. Then, 30 nM insulin or 200 µM of BSA-bound oleic acid was added to culture medium for another 24 hours. For the control group,
the same volume of treatment DMEM medium was added
to each well. After incubation with insulin or oleic acid,
cells were collected and cells were lysed with RIPA buffer
(200 µL/well) for protein sample and RNA samples were
isolated using TRIzol reagent. Cellular glycogen and triglyceride were extracted and quantified using the Glycogen
Assay and Serum Triglyceride Determination kits (SigmaAldrich). Values were normalized by total cellular protein
amount. LOC157273 and PPP1R3B expression levels were
measured using RT-qPCR (Thermo Scientific). Experiments
were done in 6 replicates and differences were evaluated
using a Student paired t test. Differences between experimental group and control group was considered significant
at P < 0.05.

RT-qPCR and Glycogen Assays for PPP1R3B
Overexpression in HuH-7 Cells
For PPP1R3B overexpression studies, cells were transfected with the pCMV6-Entry vector expressing
PPP1R3B3 cDNA or a control empty pCMV6-Entry
vector using FuGENE transfection reagent (Thermo
Scientific). Posttransfection (48 hours), cells stably expressing these genes were selected with G-418 for 72
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mL penicillin-streptomycin. After 40 hours of incubation,
upon reaching confluence, cells were washed twice with
PBS and treatment media was added. Treatment media
consisted of serum-free DMEM, 12.5 mM glucose with
100 U/mL penicillin-streptomycin for 4 hours, and then
cells were treated with either 30 nM of insulin or 200 µM
of BSA-bound oleic acid with 12.5 mM glucose DMEM
no-serum medium for 24 hours. In the control group, the
same volume of treatment DMEM medium was added
into each well. After 24 hours of treatment with either
insulin or oleic acid, HuH-7 cells were washed and harvested. Cell lysate was collected with ddH2O (100 µL/well)
as a glycogen sample or lysis with RIPA buffer (200 µL/
well) for a protein sample and RNA samples were isolated from these cells by using TRIzol reagent. RNA samples were used to measured LOC157273 and PPP1R3B
mRNA levels using RT-quantitative PCR (RT-qPCR).
The superscript VILO reverse transcriptase kit (Life
Technologies) was used to synthesize the first strand
cDNA. RT-qPCR was performed using TaqMan Gene
Expression assays and ELF1 probes (Life Technologies)
were used as controls. Total cellular glycogen was quantified using the Glycogen Assay Kit (Sigma-Aldrich).
Values were normalized by total cellular protein amount.
Experiments were done in 6 replicates and differences
were evaluated using a paired Student t test. Difference
between experimental and control groups was considered
significant at P < 0.05.
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RT-qPCR and Glycogen Assays for PPP1R3B
Knock Down in HuH-7 Cells
For PPP1R3B knock-down studies, PPP1R3B was knocked
down using CRISPR-Cas9 to create a homozygous premature stop codon with nonsense-mediated decay. Cells
including mock and homozygous PPP1R3B deletion were
included. Cell lysate was collected with ddH2O (100 µL/
well) as a glycogen sample or lysis with RIPA buffer
(200 µL/well) for a protein sample and RNA samples were
isolated using TRIzol reagent. PPP1R3B mRNA level was
measured using RT-qPCR. Cells were processed and total
protein and glycogen measured as described previously.
Experiments were done in triplicate and differences were
evaluated using a paired Student t test. Difference between
experimental and control groups was considered significant
at P < 0.05.

LOC157273 RNA In Situ Hybridization
HuH-7 cells were grown on poly-D-lysine coated glass
coverslips in 6-well plates in high glucose (4.5 mg/mL)
C-DMEM medium. After 24 hours, cells were washed
with PBS, fixed in 4% (w/v) paraformaldehyde (Fisher
Scientific) in PBS for 15 minutes, then LOC157273 RNA
in situ hybridization was done with cells on the coverslips
using RNAscope 2.5 Chromogenic Assay (Duplex) from
Advanced Cell Diagnostics according to the manufacturer’s
protocol. Cells were also probed with a baculoviral clone
including the PPP1R3B and LOC157273 genomic region
to visualize the locus.

Phenome-Wide Association Study (PheWAS)
We assessed the effect of rs4841132 on metabolic traits
from previously published GWAS (19, 27-36).

Results
To determine whether variants near PPP1R3B associate
with liver attenuation across ancestries, we examined
genotype data for 16 234 participants from the Genetics
of Obesity-associated Liver Disease (GOLD) Consortium
(Supplementary Tables 1-5 (4)). We found that among variants on the exome chip, rs4841132-A had the strongest
association with increased liver attenuation (Fig. 1). Two
coding variants in PPP1R3B did not associate with liver
attenuation (Supplementary Table 9 (4)). rs4841132-A
(P = 0.32), unlike rs738409 (PNPLA3, P = 5 × 10-22)
and rs58542926 (TM6SF2, P = 1.66 × 10-17) does not
associate with hepatic steatosis as measured using magnetic resonance imaging proton density fat fraction in
the UKBB (Supplementary Table 10 (4)). Rs4841132-A
(P = 0.43), unlike rs738409 (PNPLA3, P = 1.9 × 10-24) and
rs58542926 (TM6SF2, P = 1.5 × 10-5) does not associate
with NAFLD in Michigan Genomics Initiative (MGI) confirming that rs4841132-A does not promote fatty liver disease (Supplementary Table 11 (4)).
We then examined the effects of rs4841132 on expression of PPP1R3B in liver tissue from the MGH
bariatric (18) and STARNET cardiac surgery (19) datasets.
rs4841132-A was significantly associated with increased
expression of PPP1R3B in liver in both datasets (Table 1,
Supplementary Table 11A (4)). We found that there was
allelic expression imbalance in STARNET at PPP1R3B
(rs330915) for rs4841132 heterozygotes versus homozygotes (P < 8.94 × 10-5; Fig. 2, Supplementary Table 11B (4)),
suggesting that the effect of rs4841132-A on PPP1R3B expression is in cis (ie, affects expression of the PPP1R3B
allele on the same chromosome). rs4841132-A decreased
LOC157273 RNA levels in both datasets (Table 1,
Supplementary Table 12A (4)). Causal inference analysis
(25) in STARNET did not support that rs4841132-A increased PPP1R3B expression was due to suppression of
LOC157273 (or vice versa, P ≈ 1).
The expression of PPP1R3B was examined in GTEx
(37) and found to be expressed not only in liver but also in
adipose tissue, muscle, and blood vessels (Supplementary
Fig. 1A (38)). Even though rs4841132-A is an eQTL for
PPP1R3B in liver (Table 1), rs4841132-A was not a statistically significant eQTL for PPP1R3B in subcutaneous or
visceral fat in the MGH dataset (Supplementary Table 11A
(4)). This was due to a lower effect of the variant on expression rather than to a difference in sample size. LOC157273
was expressed at very low levels in multiple tissues in GTEx
(Supplementary Fig. 1B (38)).
To test whether changes in the genomic region of
rs4841132 affected PPP1R3B expression and glycogen
levels, we used CRISPR-Cas9 to create 105 bp homozygous
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hours. Medium was changed and fresh G-418 was added
every 2 days. After 3 days, cells stably overexpressing
the PPP1R3B3 were collected and the total cellular
RNA extracted using TRIzol reagent. Overexpression
was measured and confirmed by qRT-PCR assay. Stable
overexpressing sublines were cultured in high glucose
(4.5 mg/mL) DMEM with 10% FBS and G-418 (10 µg/
mL). After 24 hours, the medium was replaced with
DMEM with 10% delipidated FBS and G-418. Cells were
processed and total protein and glycogen measured as described previously. Experiments were done in triplicate
and differences were evaluated using a paired Student t
test. Difference between experimental and control groups
was considered significant at P < 0.05.
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Table 1. (A) Liver eQTL results for PPP1R3B and LOC157273
RNA; (B) PPP1R3B and LOC157273 gene expression changes
with a 100 bp deletion eliminating rs4841132 region in
human HuH7 cells
(A)
Cohort

Variant

Effect
allele

Transcript

Fold- P value
change

Massachusetts General Hospital
rs4841132 A

PPP1R3B

1.12

1.00E-22

rs4841132 A

LOC157273

0.90

2.38E-14

Stockholm-Tartu Atherosclerosis Reverse Networks Engineering
Task Study
rs4841132 A

PPP1R3B

1.39

3.50E-05

rs4841132 A

LOC157273

0.45

2.00E-25

(B)
Gene

Fold-changeP value

PPP1R3B

1.66

< 0.01

LOC157273 0.34

< 0.01

Cohort: Massachusetts General Hospital, expression by array (17)) or
STARNET (expression by RNA sequencing (18)). Effect allele, allele for which
direction of effect is given; transcript, transcript for the gene product (standard
symbol) in which change in expression noted; fold-change: fold-change in expression of transcript per effect allele in liver; P value: P value of association
of the variant with gene probe intensity (Massachusetts General Hospital) or
adjusted gene read counts (STARNET).

or heterozygous deletion of the area inclusive of this variant
in HuH-7 cells. We measured glycogen in cells that had been
glucose starved and then changed to medium glucose media
with or without insulin or oleic acid. We found that insulin
or oleic acid stimulation slightly increased glycogen levels
in wild-type HuH-7 cells with a concomitant decrease in
PPP1R3B and LOC157273 RNA. Cells with a homozygous or heterozygous 105 bp deletion of LOC157273 at
rs4841132 had higher glycogen levels in control and stimulated conditions. Uniformly, cells with a homozygous or
heterozygous 105bp deletion of LOC157273 at rs4841132
had increased PPP1R3B RNA and decreased LOC157273
RNA under control and stimulated conditions (Fig. 3,
Table 1). This expression pattern matches what is seen in
the human liver eQTL data from our 2 cohorts (Table 1)
and shows that these engineered cell lines perfectly model
rs4841132-A effects on LOC157273 and PPP1R3B
RNA expression. The effect of insulin and oleic acid on
PPP1R3B RNA was magnified in cells with a homozygous or heterozygous 105 bp deletion of LOC157273 at
rs4841132 where PPP1R3B RNA increased by 1.34- and
2.76-fold with insulin and 2.68- and 2.16-fold with oleic
acid versus control (Fig. 3B). These results suggest that
there may be a gene by environment interaction effect at
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Figure 1. Association of rs4841132 with liver attenuation across studies and ancestries. (A) Effect of index variants on liver attenuation by study
(European [EUR]; African American [AFA]; Hispanic [HIS]; Chinese [CHN]) and (B) by ancestry. Effect allele frequency (EAF) is listed with the corresponding P value (P), effect size on the inverse-normally transformed scale (Beta), and 95% confidence interval in effect size (95% CI) for association
with liver attenuation adjusted for age, age2, sex, alcoholic drinks per week, and population substructure. Values greater than 0 indicate an increase
in the amount of liver attenuation. For the pooled analyses, heterogeneity P values are also reported. Effect sizes and confidence intervals are summarized in the Forest plots at right. The solid vertical line represents beta = 0.
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this locus. Although cells with a heterozygous 105 bp deletion of LOC157273, under some circumstances, had higher
glycogen and PPP1R3B RNA than cells with a homozygous 105 bp deletion of LOC157273, this was not always
the case (oleic acid stimulated cells had more PPP1R3B
RNA in homozygous than heterozygous cells). That we see
an effect on glycogen in cells with a homozygous and heterozygous 105 bp deletion of LOC157273 suggests that
the effect is dominant.
The variant rs4841132 is located in the second exon of
a noncoding region of the genome denoted LOC157273.
LOC157273 is not found in nonprimates and is found
in only some primate species. We did not find homology
of LOC157273 with any coding gene in the genome.
LOC157273 appears to be widely expressed at low levels
(Supplementary Fig. 1B (38)). To test whether increase
or decrease in LOC157273 RNA would phenocopy the
effects of rs4841132-A, we overexpressed LOC157273
in HuH-7 cells using a cytomegalovirus promoter or
reduced its levels using ASOs, respectively. Increasing
LOC157273 decreased glycogen levels irrespective of
stimulation status (Fig. 4A). Despite LOC157273 being
more than 90-fold higher than baseline, PPP1R3B RNA
was only slightly reduced from baseline (Fig. 4B). When
LOC157273 was decreased, there was a slight increase in
glycogen after stimulation with insulin or oleic acid but
not without stimulation (Fig. 4C). When LOC157273
RNA was reduced, PPP1R3B RNA was lower than
baseline in both unstimulated and stimulated conditions (Fig. 4D). Therefore, even though overexpression
or knockdown of LOC157273 RNA decreased and

increased glycogen, respectively, its effects on PPP1R3B
RNA did not match the pattern seen with rs4841132-A
in human liver.
To determine whether increased or decreased expression of PPP1R3B RNA would phenocopy the effects of
rs4841132-A, PPP1R3B was overexpressed using a cytomegalovirus promoter or knocked down using CRISPRCas9 to create a homozygous premature stop codon
with nonsense mediated decay. We found that increasing
PPP1R3B expression increased glycogen (Fig. 5A). Cells
expressing the premature stop in PPP1R3B had decreased
glycogen (Fig. 5C). In both increased and decreased
PPP1R3B, expression of LOC157273 RNA increased
(Fig. 5B, D), which does not mimic the pattern seen with
rs4841132-A in human liver.
Causal inference analysis in the STARNET dataset
suggested that PPP1R3B expression is not dependent on
LOC157273 expression and vice versa. Allelic imbalance
analysis (Fig. 2) suggested that the effect of rs4841132-A
on PPP1R3B RNA was in cis. To determine whether
LOC157273 RNA was present on the DNA in cis to potentially produce an effect, we carried out fluorescence
in situ hybridization for LOC157273 in HuH-7 cells.
LOC157273 was found in 2 distinct loci in the nucleus
but these were not at the genomic site where LOC157273
or PPP1R3B are transcribed (Supplementary Fig. 2 (38)).
Taken together, these data suggest that the LOC157273
RNA is not acting in cis to affect PPP1R3B RNA levels.
Altering levels of LOC157273 can affect glycogen levels
but this is not through affecting PPP1R3B RNA levels
and vice versa. These data demonstrate that perturbation
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Figure 2. Allele-specific expression shows that rs4841132-A increases PPP1R3B expression in cis. (A) Theoretical ratio of PPP1R3B RNA transcripts
with respect to rs4841132 genotype and (B) PPP1R3B allelic balance is closer to 1 in rs4841132-G/G individuals than in rs4841132-A/G individuals suggesting a cis effect of rs4841132-A. Box plots: dark line indicates the median value, a box indicating the 25th and 75th percentiles, whiskers extending
from the median for twice the interquartile range, and individual points representing measurements outside that interval.

The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. XX, No. XX

of the DNA region at rs4841132 mimics the decrease in
LOC157273 RNA, increase in PPP1R3B RNA and increase in glycogen seen with rs4841132-A, whereas altering
the levels of PPP1R3B or LOC157273 RNA individually
does not result in this pattern of effects.
To determine the impact of rs4841132 on cardiometabolic
disease, we examined the effect of rs4841132-A on outpatient measures and diagnoses from the MGI biobank
(Fig. 6, Supplementary Table 11 (4)). The minor allele
rs4841132-A (minor allele frequency [MAF] = 0.09)
was associated with higher alanine aminotransferase
(P = 4.22 × 10-4), a marker of hepatocellular damage, alkaline phosphatase (P = 2.46 × 10-5), a marker of liver
infiltrative disease and cirrhosis (P = 0.012) while associating with decreased total serum bilirubin (P = 3.55 × 10-3).
rs4841132-A was not associated with a diagnosis of
NAFLD (P = 0.44) (Supplementary Table 10 (4)) consistent
with our previous data (2).

Examination of the effect of rs4841132-A in published
GWAS of metabolic traits (Fig. 5, Supplementary Tables 13
(4)) (27-36) revealed rs4841132-A was significantly associated with increased serum triglyceride (P = 2.59 × 10-5)
and lower serum high density lipoprotein cholesterol
(HDL; P = 4.83 × 10-45), low density lipoprotein cholesterol (LDL; p = 3.70 × 10-23) and total serum cholesterol
(P = 1.24 × 10-34). rs4841132-A was significantly associated
with higher waist-to-hip ratio (P = 2.30 × 10-3) adjusted for
body mass index, fasting blood glucose (P = 7.69 × 10-6), insulin (P = 8.84 × 10-4), serum lactate (P = 1.60 × 10-9), and
increased prevalence of type 2 diabetes (P = 2.00 × 10-3).
In the UKBB (Fig. 5, Supplementary Table 14 (4)),
rs4841132-A was significantly associated with increased
hypertension (P = 1.10 × 10-3) and red blood cell percent/
count; but, associated with decreased neutrophil percent/
count (P = 3.18 × 10-9) and decreased prevalence of ischemic heart disease (P = 0.04). In a large meta-analysis
of nuclear magnetic resonance (NMR)-measured serum
metabolites (39) (Fig. 5, Supplementary Table 13 (4)),
rs4841132-A was associated (P < 0.011) with higher
glycine, lactate, glucose, triglyceride levels on very-lowdensity lipoprotein (VLDL), and triglyceride levels on small
HDL. rs4841132-A was associated with decreased HDL
cholesterol particles, phospholipids, lipids, cholesterol esters, and free cholesterol on HDL. rs4841132-A was also
associated with lower products of fatty acid oxidation
(β-hydroxybutyrate, acetoacetate), APOA1, and free and
total HDL, LDL, and total cholesterol. These define a metabolic signature of rs4841132-A and perhaps of increased
liver glycogen status. Two coding variants in PPP1R3B did
not associate with cardiometabolic traits similar to what is
seen with rs4841132-A (Supplementary Tables 15-19 (4)).

Discussion
Using multiple population-based cohorts, we have shown
that a common variant, rs4841132, near PPP1R3B, was
associated with liver attenuation. Our query of published
studies revealed rs4841132-A was also associated with increased obesity, hypertension, insulin resistance, and decreased serum HDL, total serum cholesterol, and ischemic
heart disease (ie, promotion of metabolic disease), but not
myocardial infarction (MI). The minor allele, rs4841132-A,
was associated with liver damage but not with a diagnosis
of NAFLD in MGI consistent with prior reports (40, 41).
We also report that rs4841132-A does not associate with
liver fat in UKBB. This lack of association of rs4841132-A
with NAFLD/liver fat is consistent with our previous report
that rs4240624, which is in high linkage disequilibrium
(LD) with rs4841132, was not associated with histologic
measures of NAFLD including steatosis, nonalcoholic
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Figure 3. CRISPR/Cas9 105 bp deletion of rs4841132 region increases
glycogen, PPP1R3B RNA, and decreases LOC157273 RNA in HuH-7 cells.
(A) Fold-change in glycogen in μg/mg protein. (B) Quantitative PCR of
PPP1R3B and LOC157273 normalized to wild-type (WT) control (black).
Control, no stimulation of cells (circles); hetero: heterozygously deleted
rs4841132 region (blue); homo, homozygously deleted rs4841132 region (red); insulin, cells treated with 30 μM insulin (squares); OA, cells
treated with 200 μM oleic acid (triangles). *P < 0.05; **P < 0.01.
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steatohepatitis, and fibrosis (2, 3). These data suggest that
rs4841132-A promotes liver disease through a mechanism
separate from promoting NAFLD. Taken together, the presence of liver damage, increased serum lactate, and increased
triglyceride levels with rs4841132-A parallels what is seen
in individuals with liver glycogen storage diseases.
Metabolic syndrome consists of having 3 or more of the
following: increased abdominal obesity (waist circumference), hypertension, serum triglyceride, insulin resistance,
and low HDL (42). Traits associated with rs4841132-A
include all 5 criteria. In addition, rs4841132-A was associated with end products of increased glycolysis (ie,
increased lactate, serum triglyceride, and glycine). These
metabolites can be used in place of glucose as an energy source by peripheral tissues and are often elevated
with increased glycogen storage and glycogen storage
diseases (43). rs4841132-A was associated with lower

β-hydroxybutyrate and acetoacetate suggesting that betaoxidation of fatty acids was reduced, further increasing
levels of fatty acids and triglyceride. Excess liver triglyceride can be transported to other tissues via VLDL, which
may explain why rs4841132-A was associated with increased serum extra-large VLDL particle concentrations,
VLDL triglyceride content, and total serum triglyceride
content. Interestingly, fasting glucose levels in individuals
with rs4841132-A were slightly increased as were insulin
levels which is not typical of most glycogen storage diseases
where often hypoglycemia is seen (43). This suggests that
rs4841132-A may lead to insulin resistance. The molecular
mechanism(s) through which rs4841132-A promotes insulin resistance, hypertension, and decreased serum HDL
are not clear. The strongest effect of rs4841132-A was
on reducing HDL and, in particular, HDL particle concentrations. This suggests that some forms of low HDL
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Figure 4. LOC157273 overexpression and knockdown decreases and increases glycogen and has variable effects on PPP1R3B RNA levels in Huh-7
cells. Overexpression of vector only or vector with LOC157273. (A) Fold change in glycogen in μg/mg protein and (B) quantitative PCR of PPP1R3B
and LOC157273 normalized to vector control. Antisense oligonucleotide knockdown of LOC157273. (C) Fold-change in glycogen in μg/mg protein and
(D) quantitative PCR of PPP1R3B and LOC157273 normalized to scrambled control. ASO, cells exposed to LOC157273 antisense oligonucleotides;
control, no stimulation of cells (circles); insulin, cells treated with 30 μM insulin (squares); LOC, cells expressing LOC157273; OA; cells treated with
200uM oleic acid (triangles); scrambled: cells exposed to scrambled oligonucleotide; vector, cells expressing vector. *P < 0.05; **P < 0.01.
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reflect high glycogen stores and explains the well-known
association between low physical activity and low HDL
(44) that, from our results here, may represent high liver
glycogen. Further, our findings suggest that a primary defect increasing glycogen storage (caused by rs4841132-A)
can secondarily reduce HDL levels, suggesting that the
known beneficial effects of exercise on metabolic syndrome traits may be mediated, in part, through a primary
reduction in glycogen energy stores. Thus, our data suggest that interventions targeting HDL directly rather than
the problem of excess energy stores and increased hepatic
glycogen will likely not be effective in curbing development or treatment of metabolic syndrome and may help

explain the failure of HDL increasing medications to improve metabolic syndrome (45).
Metabolic syndrome is associated with increased risk of
MI in epidemiological studies (46). It has been recently suggested that variants that increase serum triglyceride production from liver increase risk of MI (47). This adds to the
more traditional view that increased serum LDL cholesterol
promotes MI. However, rs4841132-A dissociates the serum
triglyceride from serum cholesterol levels. In rs4841132-A
individuals, reduced prevalence of MI tracked with reduced
serum total LDL cholesterol and not with increased total
serum triglyceride. This is particularly evident in the NMR
metabolomics analyses where most rs4841132-A-associated
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Figure 5. Overexpression and knockout of PPP1R3B increases and decreases glycogen and has variable effects on LOC157273 RNA levels in HuH-7
cells. Overexpression of vector or vector with PPP1R3B. (A) Fold-change in glycogen in μg/mg protein and (B) QPCR of PPP1R3B and LOC157273
normalized to vector control. Knockout of PPP1R3B with CRISPR-Cas9 engineered insertion causing protein early termination and nonsense mediated decay. (C) Fold-change in glycogen in μg/mg protein and (D) quantitative PCR of PPP1R3B and LOC157273 normalized to HuH-7 control. Control,
no stimulation of cells; KO, knock-out; OE, overexpression; vector, cells expressing vector. P value between experimental (red) and control (black)
conditions are noted, with * representing P < 0.05.
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VLDL fractions were enriched for triglyceride at the expense of cholesterol. This suggests that at least higher triglyceride levels in rs4841132-A individuals do not increase
MI risk. Our results suggest that strategies to reduce serum
LDL cholesterol are more likely to reduce risk of MI than
strategies to reduce serum triglyceride in rs4841132 individuals. Although lower cholesterol synthesis can be seen

with high bilirubin levels, here rs4841132-A associates with
lower total serum cholesterol and lower serum bilirubin.
The mechanism behind this remains to be determined.
rs4841132-A was associated with increased red blood
cell count and decreased neutrophil count. Most glycogen
storage diseases are associated with anemia (48). The
mechanism to explain why rs4841132-A is associated
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Figure 6. Pleiotropic effects of rs4841132. Each row summarizes the effect of rs4841132-A on a trait using an additive model. Trait names (Traits) are
grouped by system. Sources include: GWAS summary statistics (public), the Michigan Genomics Initiative (MGI), or the UK Biobank (UKBB). For each
trait, effect sizes (beta) are in common units with a P value (pval) and corresponding z score from the largest analysis in source manuscripts. The z
scores are graphically summarized to the right; a red bar indicates rs4841132-A associates with an increase, whereas a blue bar indicates a decrease.
GWAS, genome-wide association study.
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in cis, than altering the RNA of these genes. However,
because altering PPP1R3B and LOC157273 RNA levels
can independently affect glycogen levels, we cannot rule
out more complex mechanisms of action at this locus.
These results corroborate the work of others showing
that overexpressing PPP1R3B in human cell lines and in
mice increases liver glycogen (49, 50). We show that the
population attributable risk of rs4841132-A in increasing
liver density (glycogen) across ancestries is large (odds of
increased liver attenuation of 2.4) for a common variant
and leads to identifiable human phenotypes and disease.
This is somewhere in between a strong Mendelian effect
and a negligibly small common effect and warrants further
investigation for clinical intervention. Loss of PPP1R3B in
mouse liver decreases liver glycogen (50, 51). We note that
2 missense variants in PPP1R3B (rs3748140, Gly48Glu,
MAF = 0.03; and rs61756425, Ser41Arg, MAF = 0.02) did
not associate with lower CT-measured liver attenuation
in our meta-analysis, nor with any other disease or metabolic measure in MGI, UKBB, or the NMR serum metabolite meta-analysis. This may be due to low power because
of low allele frequency, our inability to quantitate low
glycogen using CT, or to these alleles not having strong effects on protein function. HuH-7 cells with a 1 bp insertion

Figure 7. Physiological model of the metabolic effects of rs4841132-A. Purple arrow and inhibition sign note putative increased and inhibitory effects
of increased PPP1R3B on the enzyme activity of glycogen synthase and glycogen phosphorylase, respectively. Green arrows represent possible net
flow of metabolites to account for traits, diseases, and metabolite levels seen in the population. Traits, diseases, or metabolites that are increased or
decreased in the population are noted in red and blue, respectively.
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with increased red blood cell percentage is not known.
Neutropenia can be seen in glycogen storage disease type
1b, where the transporter for glucose-6-phosphate is affected and causes a problem with dephosphorylation of
glucose-6-phosphate to glucose to cause fasting hypoglycemia (43). rs4841132-A was not associated with fasting
hypoglycemia, so it is not clear whether the mechanism
causing neutropenia is the same in rs4841132-A as in
glycogen storage disease type 1b.
PPP1R3B encodes the glycogen-targeting subunit for
protein phosphatase 1, which increases the activity of
glycogen synthase and decreases the activity of glycogen
phosphorylase, thereby increasing glycogen accumulation (49). We show that deleting the rs4841132 region increases PPP1R3B RNA, decreases LOC157273 RNA, and
increases glycogen, perfectly phenocopying the effects of
rs4841132-A. Although increasing PPP1R3B or decreasing
LOC157273 RNA can increase glycogen, altering the expression of these genes separately does not invariably decrease LOC157273 RNA or increase PPP1R3B RNA,
respectively, which is what is seen with rs4841132-A.
This suggests that the deletion of the region and an effect
of the DNA alteration in cis better mimics the biology of
rs4841132-A which also affects expression of PPP1R3B
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in both copies of PPP1R3B, resulting in a premature stop
codon, significantly decreased (but did not eliminate)
glycogen in our experiments. Why then has PPP1R3B not
been reported as a glycogen storage disease gene type 0?
One possibility is that complete loss of PPP1R3B may be
lethal in humans. Alternatively, and consistent with our results, residual glycogen synthesis may still occur in the absence of PPP1R3B, which may prevent the subtle clinical
manifestations of glycogen storage disease type 0.
These results represent the largest genetic analysis of
liver attenuation, allowing us to identify mechanisms by
which this common noncoding variant appears to promote
glycogen storage disease. Adding to our understanding of
human metabolic disease, we show that elevated hepatic
glycogen is one cause of metabolic syndrome that does not
invariably increase risk of MI. We also show that elevated
hepatic glycogen in the population does lead to cirrhosis;
however, this work is not without limitations. Some of
the phenotypes examined are from hospital-based collections that may vary from the population norm. Further,
phenotypes of any particular individual with rs4841132-A
may vary from population averages based on other personal characteristics, including genetic background, environmental exposures, and behaviors. Likewise, we cannot
rule out the contributory role of other variants in LD with
rs4841132 but these would have to be within the 105 bp
window deleted, which functionally explains the phenotype. Finally, we cannot rule out that LOC157273 RNA
may have effects on liver or other human phenotypes.
In summary, we show that deleting the region
encompassing rs4841132-A increases PPP1R3B RNA,
decreases LOC157273 RNA, and increases glycogen that
phenocopies the pathology of rs4841132-A, which we
propose causes pathology by increasing hepatic glycogen
storage (Fig. 7). rs4841132-A promotes metabolic syndrome but protects against MI. These results are medically
important in that they define the mechanism by which a
noncoding variant causes human disease and suggest that
metabolic syndrome may be a high glycogen state and that
high serum triglycerides do not invariably lead to increased
myocardial infarction.
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